Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of NMRA-335140 in major depressive disorder
2023-506335-15-00Phase 3Completed
- Sponsor
- Neumora Therapeutics, Inc.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing NMRA-335140 with Placebo (2 arms). Primary endpoint: Change in MADRS total score from baseline to Week 6. Started Jun 2024; status: completed.
02
Drugs
navacaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2023-506335-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506335-15-00.